Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06GUG
|
|||
| Former ID |
DIB011359
|
|||
| Drug Name |
BTT-1023
|
|||
| Synonyms |
SI-3106; SI-636; Fully human VAP-1 mAbs (inflammation), BioTie/Seikagaku; Fully human VAP-1 monoclonal antibody (inflammation), BioTie/Seikagaku; VAP-1 antibody (rheumatoid arthritis/psoriasis), BioTie
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Psoriasis vulgaris [ICD-11: EA90; ICD-9: 696] | Phase 2 | [1] | |
| Company |
BioTie Therapies Corp
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Membrane copper amine oxidase (AOC3) | Target Info | . | [2] |
| BioCyc | Phenylethylamine degradation I | |||
| Spermine and spermidine degradation I | ||||
| KEGG Pathway | Glycine, serine and threonine metabolism | |||
| Tyrosine metabolism | ||||
| Phenylalanine metabolism | ||||
| beta-Alanine metabolism | ||||
| Metabolic pathways | ||||
| Panther Pathway | Phenylethylamine degradation | |||
| Pathwhiz Pathway | Beta-Alanine Metabolism | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02239211) A Trial of BTT1023 in Patients With Primary Sclerosing Cholangitis. U.S. National Institutes of Health. | |||
| REF 2 | Preclinical evaluation of a radioiodinated fully human antibody for in vivo imaging of vascular adhesion protein-1-positive vasculature in inflammation. J Nucl Med. 2013 Aug;54(8):1315-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.